Option Care Health is a premier national provider of home and alternate site infusion therapy services, employing a team of nurses, pharmacists, and dietitians who collaborate closely to deliver tailored support to patients.
CEO John Rademacher leads Option Care Health and looks to build on its legacy by injecting fresh energy and ambition to connect clinical expertise to patient outcomes.
Our Commitment to You
As a trusted partner for physician practices, patients, and payors, we aim to deliver an effortless experience that provides high-quality healthcare at cost-effective pricing, with years of investing through market cycles and seizing opportunities in an industry with fragmentation and high growth.
Compelling Financial Benefits
The combined company is expected to realize significant operating and supply chain efficiencies, producing over $60 million net synergies in 24 months at the total run rate. Furthermore, expanding home health and hospice services and strengthening its standing as an industry leader in infusion pharmacy should add substantial scale benefits and revenue enhancement.
With an experienced national clinical workforce and 674 care sites dedicated to providing high-quality alternate site healthcare, the combined company is uniquely equipped to meet the needs of health systems that want a single provider for home health, infusion therapy, hospice, and palliative pathways and transitions. Furthermore, this combined entity should foster relationships with payors by offering innovative programs that deliver higher-quality care at more cost-effective prices.
Option Care Health and BioScrip’s planned merger is expected to create an impressive infusion pharmacy and nursing network with national reach, meeting the growing demands from physicians and patients seeking complex infusion therapies for various conditions, such as anti-infectives, nutritional support, immunology, or neurologic disorders.
John Rademacher, CEO of Option Care Health, and Mike Shapiro, CFO of BioScrip, will remain with the combined company after closing their respective transactions. This merger is set to close during the second quarter of 2023, subject to customary closing conditions such as regulatory approvals. Madison Dearborn Capital Partners will remain the combined company’s lead investor and maintain majority ownership. Jefferies LLC and Moelis & Company LLC served as joint financial advisors to BioScrip, while Gibson Dunn & Crutcher LLP provided legal guidance. Goldman Sachs & Co LLC and BofA Merrill Lynch provided financial guidance, while Kirkland & Ellis LLP provided legal advice.
No matter your experience or level, option care health offers opportunities and growth for healthcare professionals of all backgrounds. With more than 6,000 teammates spanning all 50 states, our collective goal is to raise the standards of home and alternate site infusion services to the highest levels possible.
Our Care & Treatment aims to ensure all patients receive top-quality care and treatment. We work closely with you and your physician to select a practical course of therapy for your condition and offer ongoing support to help meet therapy goals.
Our nationwide network of care centers spans more than 674 locations in 46 states. It is supported by teams of nurses and pharmacists who deliver medically complex medications, treatments, and other ancillary therapies via infusion pharmacies, home health visits, or stand-alone infusion suites. In addition, we provide various supportive care services like intake coordination, insurance authorization resources for financial assistance, education, and tailored treatments exclusively for each client.
At CareTend Pharmacy Group, our commitment is to enhance the quality of care through cutting-edge technology and data analytics. Through partnerships with WellSky and other top providers of infusion care technology, we have access to revolutionary innovations, workflow enhancements, and clinical improvements within CareTend for faster innovation deployment and cost control/performance monitoring of infusion care for customers.
Executives noted that the combined company would be better suited to serve health systems, payers, and referral sources needing end-to-end home-based care solutions, such as health systems or payers looking for one partner offering all home care solutions. Both firms boast vital track records, working closely with payers to provide consistent high-quality care at reasonable costs, and are expected to serve as more vital partners as the industry moves toward value-based payment models.
The merger remains subject to typical closing conditions and shareholder approval; both boards of both companies have approved it. When completed, the new company will keep Option Care Health’s name and corporate headquarters in Bannockburn, Ill., while Amedisys locations in Baton Rouge and Nashville remain intact. Ultimately, this merger will bring over 8,000 employees and 674 care centers under one roof.
Our Commitment to Our Patients
The company strives to offer high-quality services to patients. They provide home and alternate site infusion therapies such as IV Antibiotics, Nutrition Support, Immunoglobulin, and Chronic Inflammatory Disorders treatments. Their therapy portfolio can be found in over 96 full-service pharmacies and 67 standalone infusion suites nationwide; additionally, they contract with managed care organizations, third-party payers, hospitals, and physician referral sources.
Amedisys’ acquisition will strengthen Apria Healthcare’s presence in home-based hospital-at-home, home health, hospice, soothing, and high acuity care services. Furthermore, this acquisition allows Amedisys to build out end-to-end home healthcare solutions when providers seek single partners capable of providing multiple services in patients’ homes.
Option Care Health (OPCH), a home health and hospice provider in Ohio, has unveiled an agreement to create one of the nation’s largest post-acute care companies by paying $3.6 billion to acquire Amedisys Inc. The acquisition will create an unprecedented home and alternate site infusion therapy services provider with nearly 6,700 employees located at 674 care centers throughout 46 states – earning an estimated total of around $6.2 billion by 2022. Option Care CEO John Rademacher will lead this new entity, while Amedisys’ Richard Ashworth will serve as a special adviser in this deal.
Option Care Health’s relationship with Amedisys predates its merger announcement; in 2021, they partnered to deliver home infusion services targeted explicitly toward COVID-19 patients. Both companies are headquartered in Bannockburn, Illinois, and will maintain Amedisys’ operations in Baton Rouge and Nashville while continuing to manage 674 care centers nationwide.
Gaining competitive, customer, and technology insights with just a few clicks. CB Insights’ research and analysis can give you confidence when making strategic decisions. Our unrivaled analyst expertise, in-depth private company data, and proprietary platform put you in control – so start your free trial now – you won’t regret it.
Option Care Health makes your career much more than a simple job – you are part of a collaborative team dedicated to raising patient care and well-being standards while earning competitive pay, full benefits, retirement savings plans, and opportunities for advancement in return.
Option Care Health is an independent home and alternate site infusion service provider. Their therapy portfolio features pharmaceuticals and complex compounded solutions distributed nationwide through 96 full-service pharmacies and 67 standalone ambulatory infusion suites. Option Care Health contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to deliver infusion therapy.
Option Care offers a variety of infusion therapies such as IV antibiotics, nutrition support, immunoglobulin, bleeding disorders treatments, heart failure therapy, and other specialized treatments. Their therapeutic services are delivered via comprehensive solutions such as intake coordination, insurance authorization, and financial assistance education plans. Based in Bannockburn, Illinois, since 1979.
Investors can trade Option Care Health stock during the Pre-Market (4:00-9:30 a.m. ET) and After-Hour Market (4:00-8:00 p.m. ET). This trading environment may offer less liquidity than regulated markets and experience rapid price movements.
Madison Dearborn Capital Partners (MDP) has over four decades of experience investing across five industry sectors, with 30 years of healthcare investing expertise. MDP works closely with leading healthcare companies that can deliver value to customers and patients while creating long-term shareholder value and companies that could become global market leaders themselves. Furthermore, Madison Dearborn invests in innovative tech companies advancing healthcare industry.